SARS-CoV-2 immunogenicity at the crossroads

Allergy. 2020 Jul;75(7):1822-1824. doi: 10.1111/all.14360. Epub 2020 May 25.
No abstract available

Keywords: infections; inflammation; lung diseases other than asthma and COPD; vaccines; virus.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Betacoronavirus / genetics
  • Betacoronavirus / immunology*
  • COVID-19
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / virology
  • Cross Reactions
  • Humans
  • Immunogenicity, Vaccine*
  • Mutation Rate
  • Pandemics / prevention & control*
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / prevention & control*
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / immunology*
  • Spike Glycoprotein, Coronavirus / metabolism
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • spike protein, SARS-CoV-2
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2